


**Product Name** : BWA-522  
**Cat. No.** : PC-21123  
**CAS No.** : 3042820-12-9  
**Molecular Formula** : C<sub>43</sub>H<sub>51</sub>ClN<sub>4</sub>O<sub>7</sub>  
**Molecular Weight** : 771.35  
**Target** : PROTAC  
**Solubility** : 10 mM in DMSO



## Biological Activity

BWA-522 is a potent, orally bioavailable **PROTAC** degrader of the androgen receptor N-terminal domain (**AR-NTD**), induces AR-FL or AR-V7 protein degradation with DC50 of 0.73 μM (AR-FL) and 0.67 μM (AR-V7) in VCaP cells.

BWA-522 is a novel and orally active AR-FL and AR-V7 PROTAC degrader.

BWA-522 inhibits the growth of AR-dependent PC cell growth, achieving IC50 values of 1.07 and 5.59 μM in LNCaP and VCaP cells.

BWA-522 effectively inhibits the growth of enzalutamide-resistant cells 22Rv1 with IC50 values of 4.08 μM, but not AR antagonist EPI-002 (IC50 > 30 μM).

BWA-522 suppresses the colony formation, inhibits the expression of AR-regulated protein, induced apoptosis in LNCaP and VCaP cells.

BWA-522 (20 or 60 mg/kg, PO) exhibits antitumor efficacy in the LNCaP xenograft tumor model in mice.

## References

Bowen Zhang, et al. *J Med Chem.* 2023 Aug 24;66(16):11158-11186.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com